Metabolomics of oxidative stress in recent studies of Endogenous and exogenously administered intermediate metabolites

International Journal of Molecular Sciences

Volumn 12, Issue 10, 2011, Pages 6469-6501

  Liu, Jia ^a   Litt, Lawrence ^a   Segal, Mark R ^b   Kelly, Mark J S ^a   Pelton, Jeffrey G ^c   Kim, Myungwon ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

Brain; Chemometrics; Heart; Kidney; Liver; Metabolomics; Metabonomics; Multivariate analysis; NMR; Oxidative stress; Principal component analysis; Proteomics; Targeted profiling; Transcriptionomics

Indexed keywords

ADENOSINE TRIPHOSPHATE; FRUCTOSE 1,6 BISPHOSPHATE; PYRUVIC ACID; PYRUVIC ACID DERIVATIVE; PYRUVIC ACID ETHYL ESTER; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ANTIOXIDANT ACTIVITY; BIOMICS; BRAIN ISCHEMIA; CHEMOMETRICS; CLINICAL TRIAL (TOPIC); CYTOSOL; DETOXIFICATION; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG STRUCTURE; ELECTRON TRANSPORT; ENERGY METABOLISM; HEART DISEASE; HUMAN; HUMAN GENOME PROJECT; INDUCED HYPOTHERMIA; KIDNEY DISEASE; LIQUID CHROMATOGRAPHY; LIVER FUNCTION; MALIGNANT NEOPLASTIC DISEASE; MASS SPECTROMETRY; METABOLITE; METABOLOMICS; METABONOMICS; MITOCHONDRION; MOLECULAR DYNAMICS; NEWBORN HYPOXIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PATTERN RECOGNITION; REVIEW; SCHIZOPHRENIA; STATISTICAL ANALYSIS; TRAUMATIC BRAIN INJURY; VASCULAR DISEASE; BRAIN; HEART MUSCLE; KIDNEY; LIVER; METABOLISM; METABOLOME; NEOPLASM; PATHOLOGY;

BRAIN; HUMANS; KIDNEY; LIVER; METABOLOME; METABOLOMICS; MYOCARDIUM; NEOPLASMS; OXIDATIVE STRESS; PYRUVATES; REACTIVE OXYGEN SPECIES;

EID: 80055034402     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms12106469     Document Type: Review

References (150)

1. Griffiths, W.J.; Koal, T.; Wang, Y.; Kohl, M.; Enot, D.P.; Deigner, H.P. Targeted metabolomics for biomarker discovery. Angew. Chem. Int. Ed. Engl. 2010, 49, 5426-5445.
2. Serkova, N.J.; Niemann, C.U. Pattern recognition and biomarker validation using quantitative H-1-NMR-based metabolomics. Expert Rev. Mol. Diagn. 2006, 6, 717-731.
3. Serkova, N.J.; Niemann, C.U. Biochemical mechanisms of nephrotoxicity: Application for metabolomics. Expert Opin. Drug Metab. Toxicol. 2007, 3, 527-544.
4. Serkova, N.J.; Reisdorph, N.A.; van Patot, M.C.T. Metabolic markers of hypoxia: Systems biology application in biomedicine. Toxicol. Mech. Methods 2008, 18, 81-95.
5. Serkova, N.J.; Spratlin, J.L.; Eckhardt, S.G. NMR-based metabolomics: Translational application and treatment of cancer. Curr. Opin. Mol. Ther. 2007, 9, 572-585.
6. Barderas, M.G.; Laborde, C.M.; Posada, M.; de la Cuesta, F.; Zubiri, I.; Vivanco, F.; Alvarez-Llamas, G. Metabolomic profiling for identification of novel potential biomarkers in cardiovascular diseases. J. Biomed. Biotechnol. 2011, 2011, 790132:1-790132:9.
7. Christians, U.; Klawitter, J.; Brunner, N.; Schmitz, V. Biomarkers of immunosuppressant organ toxicity after transplantation: Status, concepts and misconceptions. Expert Opin. Drug Metab. Toxicol. 2011, 7, 175-200.
8. Davis, V.W.; Bathe, O.F.; Schiller, D.E.; Slupsky, C.M.; Sawyer, M.B. Metabolomics and surgical oncology: Potential role for small molecule biomarkers. J. Surg. Oncol. 2011, 103, 451-459.
9. Lane, A.N.; Fan, T.W.; Bousamra, M.; Higashi, R.M.; Yan, J.; Miller, D.M. Stable isotope-resolved metabolomics (SIRM) in cancer research with clinical application to nonsmall cell lung cancer. OMICS 2011, 15, 173-182.
10. Li, N.; Liu, J.Y.; Qiu, H.; Harris, T.R.; Sirish, P.; Hammock, B.D.; Chiamvimonvat, N. Use of metabolomic profiling in the study of arachidonic acid metabolism in cardiovascular disease. Congest Heart Fail 2011, 17, 42-46.
11. Nagrath, D.; Caneba, C.; Karedath, T.; Bellance, N. Metabolomics for mitochondrial and cancer studies. Biochim. Biophys. Acta 2011, 1807, 650-663.
12. Rubakhin, S.S.; Romanova, E.V.; Nemes, P.; Sweedler, J.V. Profiling metabolites and peptides in single cells. Nat. Methods 2011, 8, S20-S29.
13. Sofia, M.; Maniscalco, M.; de Laurentiis, G.; Paris, D.; Melck, D.; Motta, A. Exploring airway diseases by NMR-based metabonomics: A review of application to exhaled breath condensate. J. Biomed. Biotechnol. 2011, 2011, 403260:1-403260:7.
14. Nicholson, J.K.; Lindon, J.C.; Holmes, E. ''Metabonomics'': Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999, 29, 1181-1189.
15. Lindon, J.C.; Holmes, E.; Bollard, M.E.; Stanley, E.G.; Nicholson, J.K. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers 2004, 9, 1-31.
16. Robertson, D.G. Metabonomics in toxicology: A review. Toxicol. Sci. 2005, 85, 809-822.
17. Fiehn, O. Combining genomics, metabolome analysis, and biochemical modelling to understand metabolic networks. Comp. Funct. Genomics 2001, 2, 155-168.
18. Bren, L. Metabolomics: Working toward personalized medicine. FDA Consum. 2005, 39, 28-33.
19. Castresana, J.; Lubben, M.; Saraste, M.; Higgins, D.G. Evolution of cytochrome oxidase, an enzyme older than atmospheric oxygen. EMBO J. 1994, 13, 2516-2525.
20. Castresana, J.; Saraste, M. Evolution of energetic metabolism: the respiration-early hypothesis. Trends Biochem. Sci. 1995, 20, 443-448.
21. Maxwell, S.R.; Thomason, H.; Sandler, D.; Leguen, C.; Baxter, M.A.; Thorpe, G.H.; Jones, A.F.; Barnett, A.H. Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus. Eur. J. Clin. Invest. 1997, 27, 484-490.
22. Moncada, S. Nitric oxide: Discovery and impact on clinical medicine. J. R. Soc. Med. 1999, 92, 164-169.
23. Koppenol, W.H.; Moreno, J.J.; Pryor, W.A.; Ischiropoulos, H.; Beckman, J.S. Peroxynitrite, a cloaked oxidant formed by nitric oxide and superoxide. Chem. Res. Toxicol. 1992, 5, 834-842.
24. Beckman, J.S.; Koppenol, W.H. Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and ugly. Am. J. Physiol. 1996, 271, C1424-C1437.
25. Pacher, P.; Beckman, J.S.; Liaudet, L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 2007, 87, 315-424.
26. Wink, D.A.; Mitchell, J.B. Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic. Biol. Med. 1998, 25, 434-456.
27. Janssen-Heininger, Y.M.; Persinger, R.L.; Korn, S.H.; Pantano, C.; McElhinney, B.; Reynaert, N.L.; Langen, R.C.; Ckless, K.; Shrivastava, P.; Poynter, M.E. Reactive nitrogen species and cell signaling: implications for death or survival of lung epithelium. Am. J. Respir. Crit. Care Med. 2002, 166, S9-S16.
28. Xu, Q.B.; Mayr, M.; Metzler, B.; Chung, Y.L.; McGregor, E.; Mayr, U.; Troy, H.; Hu, Y.H.; Leitges, M.; Pachinger, O.; Griffiths, J.R.; Dunn, M.J. Ischemic preconditioning exaggerates cardiac damage in PKC-delta null mice. Am. J. Physiol.-Heart Circ. Physiol. 2004, 287, H946-H956.
29. Markov, A.K.; Oglethorpe, N.C.; Blake, T.M.; Lehan, P.H.; Hellems, H.K. Hemodynamic, electrocardiographic, and metabolic effects of fructose diphosphate on acute myocardial ischemia. Am. Heart J. 1980, 100, 639-646.
30. Markov, A.K. Hemodynamics and metabolic effects of fructose 1-6 diphosphate in ischemia and shock-Experimental and clinical observations. Ann. Emerg. Med. 1986, 15, 1470-1477.
31. Farias, L.A.; Willis, M.; Gregory, G.A. Effects of fructose-1,6-diphosphate, glucose, and saline on cardiac resuscitation. Anesthesiology 1986, 65, 595-601.
32. Kuluz, J.W.; Gregory, G.A.; Han, Y.; Dietrich, W.D.; Schleien, C.L. Fructose-1,6-bisphosphate reduces infarct volume after reversible middle cerebral artery occlusion in rats. Stroke 1993, 24, 1576-1583.
33. Kelleher, J.A.; Gregory, G.A.; Chan, P.H. Effect of fructose-1,6-bisphosphate on glutamate uptake and glutamine synthetase activity in hypoxic astrocyte cultures. Neurochem. Res. 1994, 19, 209-215.
34. Kelleher, J.A.; Chan, T.Y.; Chan, P.H.; Gregory, G.A. Protection of astrocytes by fructose 1,6-bisphosphate and citrate ameliorates neuronal injury under hypoxic conditions. Brain Res. 1996, 726, 167-173.
35. Gobbel, G.T.; Chan, T.Y.; Gregory, G.A.; Chan, P.H. Response of cerebral endothelial cells to hypoxia: Modification by fructose-1,6-bisphosphate but not glutamate receptor antagonists. Brain Res. 1994, 653, 23-30.
36. Markov, A.K.; Warren, E.T.; Cohly, H.H.; Sauls, D.J.; Skelton, T.N. Influence of fructose-1,6-diphosphate on endotoxin-induced lung injuries in sheep. J. Surg. Res. 2007, 138, 45-50.
37. Kaakinen, T.; Heikkinen, J.; Dahlbacka, S.; Alaoja, H.; Laurila, P.; Kiviluoma, K.; Salomaki, T.; Romsi, P.; Tuominen, H.; Biancari, F. et al. Fructose-1,6-bisphosphate supports cerebral energy metabolism in pigs after ischemic brain injury caused by experimental particle embolization. Heart Surg. Forum 2006, 9, E828-E835.
38. Trimarchi, G.R.; Arcadi, F.A.; de Luca, R.; Imperatore, C.; Santoro, G.; Trimarchi, F.; Costa, G. Neuroprotective activity of fructose-1,6-bisphosphate following transient forebrain ischemia in the Mongolian gerbil. Jpn. J. Pharmacol. 1993, 62, 215-222.
39. Bickler, P.E.; Buck, L.T. Effects of fructose-1,6-bisphosphate on glutamate release and ATP loss from rat brain slices during hypoxia. J. Neurochem. 1996, 67, 1463-1468.
40. Bickler, P.E.; Kelleher, J.A. Fructose-1,6-bisphosphate stabilizes brain intracellular calcium during hypoxia in rats. Stroke 1992, 23, 1617-1622.
41. LeBlanc, M.H.; Farias, L.A.; Markov, A.K.; Evans, O.B.; Smith, B.; Smith, E.E.; Brown, E.G. Fructose-1,6-diphosphate, when given five minutes after injury, does not ameliorate hypoxic ischemic injury to the central nervous system in the newborn pig. Biol. Neonate 1991, 59, 98-108.
42. LeBlanc, M.H.; Farias, L.A.; Evans, O.B.; Vig, V.; Smith, E.E.; Markov, A.K. Fructose-1,6-bisphosphate, when given immediately before reoxygenation, or before injury, does not ameliorate hypoxic ischemic injury to the central nervous system in the newborn pig. Crit. Care Med. 1991, 19, 75-83.
43. Fujii, E.; Kodama, Y.; Takahashi, N.; Roman, C.; Ferriero, D.; Gregory, G.; Parer, J.T. Fructose-1,6-bisphosphate did not affect hippocampal neuronal damage caused by 10 min of complete umbilical cord occlusion in fetal sheep. Neurosci. Lett. 2001, 309, 49-52.
44. Vexler, Z.S.; Wong, A.; Francisco, C.; Manabat, C.; Christen, S.; Tauber, M.; Ferriero, D.M.; Gregory, G. Fructose-1,6-bisphosphate preserves intracellular glutathione and protects cortical neurons against oxidative stress. Brain Res. 2003, 960, 90-98.
45. Mazzio, E.A.; Soliman, K.F. Cytoprotection of pyruvic acid and reduced beta-nicotinamide adenine dinucleotide against hydrogen peroxide toxicity in neuroblastoma cells. Neurochem. Res. 2003, 28, 733-741.
46. Park, J.Y.; Kim, E.J.; Kwon, K.J.; Jung, Y.S.; Moon, C.H.; Lee, S.H.; Baik, E.J. Neuroprotection by fructose-1,6-bisphosphate involves ROS alterations via p38 MAPK/ERK. Brain Res. 2004, 1026, 295-301.
47. Fahn, S.; Cohen, G. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it. Ann. Neurol. 1992, 32, 804-812.
48. Ying, W.; Chen, Y.; Alano, C.C.; Swanson, R.A. Tricarboxylic acid cycle substrates prevent PARP-mediated death of neurons and astrocytes. J. Cereb. Blood Flow Metab. 2002, 22, 774-779.
49. Zeng, J.; Hirai, K.; Yang, G.Y.; Ying, W.; Swanson, R.A.; Kelly, M.; Mayer, M.; James, T.L.; Litt, L. Using 31P NMR spectroscopy at 14.1 Tesla to investigate PARP-1 associated energy failure and metabolic rescue in cerebrocortical slices. J. Bioenerg. Biomembr. 2004, 36, 415-419.
50. Fink, M.P. Ringer's ethyl pyruvate solution: A novel resuscitation fluid. Minerva Anestesiol. 2001, 67, 190-192.
51. Fink, M.P. Reactive oxygen species as mediators of organ dysfunction caused by sepsis, acute respiratory distress syndrome, or hemorrhagic shock: Potential benefits of resuscitation with Ringer's ethyl pyruvate solution. Curr. Opin. Clin. Nutr. Metab. Care 2002, 5, 167-174.
52. Varma, S.D.; Devamanoharan, P.S.; Ali, A.H. Formation of advanced glycation end (AGE) products in diabetes: Prevention by pyruvate and alpha-keto glutarate. Mol. Cell. Biochem. 1997, 171, 23-28.
53. Varma, S.D.; Devamanoharan, P.S.; Ali, A.H. Prevention of intracellular oxidative stress to lens by pyruvate and its ester. Free Radic. Res. 1998, 28, 131-135.
54. Varma, S.D.; Hegde, K.R.; Kovtun, S. Oxidative damage to lens in culture: Reversibility by pyruvate and ethyl pyruvate. Ophthalmologica 2006, 220, 52-57.
55. Liu, J.; Segal, M.; Yoo, S.; Yang, G.Y.; Kelly, M.; James, T.L.; Litt, L. Antioxidant effect of ethyl pyruvate in respiring neonatal cerebrocortical slices after H(2)O(2) stress. Neurochem. Int. 2009, 54, 106-110.
56. Huh, S.H.; Chung, Y.C.; Piao, Y.; Jin, M.Y.; Son, H.J.; Yoon, N.S.; Hong, J.Y.; Pak, Y.K.; Kim, Y.S.; Hong, J.K. et al. Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson's disease. J. Immunol. 2011, 187, 960-969.
57. Varma, S.D.; Hegde, K.R. Kynurenine-induced photo oxidative damage to lens in vitro: Protective effect of caffeine. Mol. Cell. Biochem. 2010, 340, 49-54.
58. Varma, S.D.; Kovtun, S.; Hegde, K.R. Role of ultraviolet irradiation and oxidative stress in cataract formation-medical prevention by nutritional antioxidants and metabolic agonists. Eye Contact Lens 2011, 37, 233-245.
59. Mouchiroud, L.; Molin, L.; Kasturi, P.; Triba, M.N.; Dumas, M.E.; Wilson, M.C.; Halestrap, A.P.; Roussel, D.; Masse, I.; Dalliere, N. et al. Pyruvate imbalance mediates metabolic reprogramming and mimics lifespan extension by dietary restriction in Caenorhabditis elegans. Aging Cell 2011, 10, 39-54.
60. Mallet, R.T.; Sun, J. Antioxidant properties of myocardial fuels. Mol. Cell. Biochem. 2003, 253, 103-111.
61. Ryou, M.G.; Flaherty, D.C.; Hoxha, B.; Gurji, H.; Sun, J.; Hodge, L.M.; Olivencia-Yurvati, A.H.; Mallet, R.T. Pyruvate-enriched cardioplegia suppresses cardiopulmonary bypass-induced myocardial inflammation. Ann. Thorac. Surg. 2010, 90, 1529-1535.
62. Mazzio, E.A.; Reams, R.R.; Soliman, K.F. The role of oxidative stress, impaired glycolysis and mitochondrial respiratory redox failure in the cytotoxic effects of 6-hydroxydopamine in vitro. Brain Res. 2004, 1004, 29-44.
63. Kang, Y.H.; Chung, S.J.; Kang, I.J.; Park, J.H.; Bunger, R. Intramitochondrial pyruvate attenuates hydrogen peroxide-induced apoptosis in bovine pulmonary artery endothelium. Mol. Cell. Biochem. 2001, 216, 37-46.
64. Pellerin, L.; Magistretti, P.J. Glutamate uptake into astrocytes stimulates aerobic glycolysis: A mechanism coupling neuronal activity to glucose utilization. Proc. Natl. Acad. Sci. USA 1994, 91, 10625-10629.
65. Berthet, C.; Lei, H.; Thevenet, J.; Gruetter, R.; Magistretti, P.J.; Hirt, L. Neuroprotective role of lactate after cerebral ischemia. J. Cereb. Blood Flow Metab. 2009, 29, 1780-1789.
66. Castro, M.A.; Beltran, F.A.; Brauchi, S.; Concha, I.I. A metabolic switch in brain: Glucose and lactate metabolism modulation by ascorbic acid. J. Neurochem. 2009, 110, 423-440.
67. Prieto, R.; Tavazzi, B.; Taya, K.; Barrios, L.; Amorini, A.M.; di Pietro, V.; Pascual, J.M.; Marmarou, A.; Marmarou, C.R. Brain energy depletion in a rodent model of diffuse traumatic brain injury is not prevented with administration of sodium lactate. Brain Res. 2011, 1404, 39-49.
68. Kimelberg, H.K. The role of hypotheses in current research, illustrated by hypotheses on the possible role of astrocytes in energy metabolism and cerebral blood flow: From Newton to now. J. Cereb. Blood Flow Metab. 2004, 24, 1235-1239.
69. Van den Berg, R.A.; van der Werf, M.J. Centering, scaling, and transformations: Improving the biological information content of metabolomics data. BMC Genomics 2006, 7, 142.
70. Eriksson, L.; Antti, H.; Gottfries, J.; Holmes, E.; Johansson, E.; Lindgren, F.; Long, I.; Lundstedt, T.; Trygg, J.; Wold, S. Using chemometrics for navigating in the large data sets of genomics, proteomics, and metabonomics (gpm). Anal. Bioanal. Chem. 2004, 380, 419-429.
71. Alam, T.M.; Alam, M.K. Chemometric analysis of NMR spectroscopy data: A review. Ann. Rep. NMR Spectrosc. 2004, 54, 41-80.
72. Weljie, A.M.; Newton, J.; Mercier, P.; Carlson, E.; Slupsky, C.M. Targeted profiling: Quantitative analysis of 1H NMR metabolomics data. Anal. Chem. 2006, 78, 4430-4442.
73. Wishart, D.S. Quantitative metabolomics using NMR. Trends Anal. Chem. 2008, 27, 228-237.
74. Provencher, S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 1993, 30, 672-679.
75. Eriksson, L.; Johansson, E.; Kettaneh-Wold, N.; Trygg, J.; Wikström, C.; Wold, S. Multi- and Megavariate Data Analysis Part I: Basic Principles and Applications, 2nd revised and enlarged edition ed.; Umetrics Academy: Umeå, Sweden, 2006; Volume 1.
76. Kemp, M.L.; Wille, L.; Lewis, C.L.; Nicholson, L.B.; Lauffenburger, D.A. Quantitative network signal combinations downstream of TCR activation can predict IL-2 production response. J. Immunol. 2007, 178, 4984-4992.
77. Parsons, H.M.; Ludwig, C.; Viant, M.R. Line-shape analysis of J-resolved NMR spectra: application to metabolomics and quantification of intensity errors from signal processing and high signal congestion. Magn. Reson. Chem. 2009, 47, S86-S95.
78. Ludwig, C.; Viant, M.R. Two-dimensional J-resolved NMR spectroscopy: Review of a key methodology in the metabolomics toolbox. Phytochem. Anal. 2010, 21, 22-32.
79. Viant, M.R.; Bundy, J.G.; Pincetich, C.A.; de Ropp, J.S.; Tjeerdema, R.S. NMR-derived developmental metabolic trajectories: An approach for visualizing the toxic actions of trichloroethylene during embryogenesis. Metabolomics 2005, 1, 149-158.
80. Lane, A.N.; Fan, T.W.-M. Quantification and identification of isotopomer distributions of metabolites in crude cell extracts using 1H TOCSY. Metabolomics 2007, 3, 79-86.
81. Lewis, I.A.; Karsten, R.H.; Norton, M.E.; Tonelli, M.; Westler, W.M.; Markley, J.L. NMR method for measuring carbon-13 isotopic enrichment of metabolites in complex solutions. Anal. Chem. 2010, 82, 4558-4563.
82. Fan, T.W.; Lane, A.N. NMR-based stable isotope resolved metabolomics in systems biochemistry. J. Biomol. NMR 2011, 49, 267-280.
83. Pontoizeau, C.; Herrmann, T.; Toulhoat, P.; Elena-Herrmann, B.; Emsley, L. Targeted projection NMR spectroscopy for unambiguous metabolic profiling of complex mixtures. Magn. Reson. Chem. 2010, 48, 727-733.
84. Gowda, G.A.; Zhang, S.; Gu, H.; Asiago, V.; Shanaiah, N.; Raftery, D. Metabolomics-based methods for early disease diagnostics. Expert Rev. Mol. Diagn. 2008, 8, 617-633.
85. Ezzati, M.; Hoorn, S.V.; Lopez, A.D.; Danaei, G.; Rodgers, A.; Mathers, C.D.; Murray, C.J.L. Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors; Ezzati, M., Lopez, A.D., Rodgers, A., Murray, C.J.L., Eds.; WHO: Geneva, Switzerland, 2006.
86. Stephan, K.E.; Baldeweg, T.; Friston, K.J. Synaptic plasticity and dysconnection in schizophrenia. Biol. Psychiat. 2006, 59, 929-939.
87. Munoz Maniega, S.; Lymer, G.K.; Bastin, M.E.; Marjoram, D.; Job, D.E.; Moorhead, T.W.; Owens, D.G.; Johnstone, E.C.; McIntosh, A.M.; Lawrie, S.M. A diffusion tensor MRI study of white matter integrity in subjects at high genetic risk of schizophrenia. Schizophr. Res. 2008, 106, 132-139.
88. Sussmann, J.E.; Lymer, G.K.; McKirdy, J.; Moorhead, T.W.; Munoz Maniega, S.; Job, D.; Hall, J.; Bastin, M.E.; Johnstone, E.C.; Lawrie, S.M.; McIntosh, A.M. White matter abnormalities in bipolar disorder and schizophrenia detected using diffusion tensor magnetic resonance imaging. Bipolar Disord. 2009, 11, 11-18.
89. Yao, J.K.; Reddy, R. Oxidative stress in schizophrenia: Pathogenetic and therapeutic implications. Antioxid. Redox Signal. 2011, 15, 1999-2002.
90. Martins-de-Souza, D.; Harris, L.W.; Guest, P.C.; Bahn, S. The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics. Antioxid. Redox Signal. 2011, 15, 2067-2079.
91. Kodavali, C.V.; Mikhil, B.N.; Vishwajit, N.L. Genetic association studies of antioxidant pathway genes and schizophrenia. Antioxid. Redox Signal. 2011, 15, 2037-2045.
92. Prabakaran, S.; Swatton, J.E.; Ryan, M.M.; Huffaker, S.J.; Huang, J.T.; Griffin, J.L.; Wayland, M.; Freeman, T.; Dudbridge, F.; Lilley, K.S. et al. Mitochondrial dysfunction in schizophrenia: Evidence for compromised brain metabolism and oxidative stress. Mol. Psychiat. 2004, 9, 684-697.
93. Quinones, M.P.; Kaddurah-Daouk, R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol. Dis. 2009, 35, 165-176.
94. Reddy, R. Antioxidant therapeutics for schizophrenia. Antioxid. Redox Signal. 2011, 15, 2047-2055.
95. Hoehn, T.; Hansmann, G.; Buhrer, C.; Simbruner, G.; Gunn, A.J.; Yager, J.; Levene, M.; Hamrick, S.E.; Shankaran, S.; Thoresen, M. Therapeutic hypothermia in neonates. Review of current clinical data, ILCOR recommendations and suggestions for implementation in neonatal intensive care units. Resuscitation 2008, 78, 7-12.
96. Gancia, P.; Pomero, G. Brain cooling therapy. Minerva Pediatr. 2010, 62, 173-175.
97. Gluckman, P.D.; Wyatt, J.S.; Azzopardi, D.; Ballard, R.; Edwards, A.D.; Ferriero, D.M.; Polin, R.A.; Robertson, C.M.; Thoresen, M.; Whitelaw, A. et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: Multicentre randomised trial. Lancet 2005, 365, 663-670.
98. Shankaran, S.; Laptook, A.R.; Ehrenkranz, R.A.; Tyson, J.E.; McDonald, S.A.; Donovan, E.F.; Fanaroff, A.A.; Poole, W.K.; Wright, L.L.; Higgins, R.D. et al. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. N. Engl. J. Med. 2005, 353, 1574-1584.
99. Seppelt, I. Hypothermia does not improve outcome from traumatic brain injury. Crit. Care Resusc. 2005, 7, 233-237.
100. Hindman, B.J.; Todd, M.M.; Gelb, A.W.; Loftus, C.M.; Craen, R.A.; Schubert, A.; Mahla, M.E.; Torner, J.C. Mild hypothermia as a protective therapy during intracranial aneurysm surgery: A randomized prospective pilot trial. Neurosurgery 1999, 44, 23-32.
101. Ramani, R. Hypothermia for brain protection and resuscitation. Curr. Opin. Anaesthesiol. 2006, 19, 487-491.
102. Bernard, S.A.; Gray, T.W.; Buist, M.D.; Jones, B.M.; Silvester, W.; Gutteridge, G.; Smith, K. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N. Engl. J. Med. 2002, 346, 557-563.
103. Nolan, J.P.; Morley, P.T.; Hoek, T.L.; Hickey, R.W. Therapeutic hypothermia after cardiac arrest. An advisory statement by the Advancement Life support Task Force of the International Liaison committee on Resuscitation. Resuscitation 2003, 57, 231-235.
104. Sugerman, N.T.; Abella, B.S. Hospital-based use of therapeutic hypothermia after cardiac arrest in adults. J. Neurotrauma 2009, 26, 371-376.
105. Sanders, A.B. Therapeutic hypothermia after cardiac arrest. Curr. Opin. Crit. Care 2006, 12, 213-217.
106. Chu, C.Y.; Xiao, X.; Zhou, X.G.; Lau, T.K.; Rogers, M.S.; Fok, T.F.; Law, L.K.; Pang, C.P.; Wang, C.C. Metabolomic and bioinformatic analyses in asphyxiated neonates. Clin. Biochem. 2006, 39, 203-209.
107. Atzori, L.; Xanthos, T.; Barberini, L.; Antonucci, R.; Murgia, F.; Lussu, M.; Aroni, F.; Varsami, M.; Papalois, A.; Lai, A. et al. A metabolomic approach in an experimental model of hypoxia-reoxygenation in newborn piglets: Urine predicts outcome. J. Matern.-Fetal Neonatal Med. 2010, 23, 134-137.
108. Liu, J.; Litt, L.; Segal, M.R.; Kelly, M.J.; Yoshihara, H.A.; James, T.L. Outcome-related metabolomic patterns from 1H/31P NMR after mild hypothermia treatments of oxygen-glucose deprivation in a neonatal brain slice model of asphyxia. J. Cereb. Blood Flow Metab. 2011, 31, 547-559.
109. Lang, A.E.; Lozano, A.M. Parkinson's disease. Second of two parts. N. Engl. J. Med. 1998, 339, 1130-1143.
110. Lang, A.E.; Lozano, A.M. Parkinson's disease. First of two parts. N. Engl. J. Med. 1998, 339, 1044-1053.
111. Beal, M.F.; Bogdanov, M.; Matson, W.R.; Wang, L.; Matson, T.; Saunders-Pullman, R.; Bressman, S.S. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 2008, 131, 389-396.
112. Fasano, M.; Alberio, T.; Lopiano, L. Peripheral biomarkers of Parkinson's disease as early reporters of central neurodegeneration. Biomarkers Med. 2008, 2, 465-478.
113. Caudle, W.M.; Bammler, T.K.; Lin, Y.; Pan, S.; Zhang, J. Using ''omics'' to define pathogenesis and biomarkers of Parkinson's disease. Expert Rev. Neurother. 2010, 10, 925-942.
114. Viant, M.R.; Lyeth, B.G.; Miller, M.G.; Berman, R.F. An NMR metabolomic investigation of early metabolic disturbances following traumatic brain injury in a mammalian model. NMR Biomed. 2005, 18, 507-516.
115. Kagan, V.E.; Tyurin, V.A.; Tyurina, Y.Y.; Borisenko, G.G.; Sokolova, T.V.; Ritov, V.B.; Quinn, P.J.; Rose, M.; Kochanek, P.; Graham, S.H. Oxidative stress following traumatic brain injury in rats: Quantitation of biomarkers and detection of free radical intermediates. J. Neurochem. 2000, 75, 2178-2189.
116. Palmer, A.M.; Marion, D.W.; Botscheller, M.L.; Swedlow, P.E.; Styren, S.D.; Dekosky, S.T. Traumatic brain injury-induced excitotoxicity assessed in a controlled cortical impact model. J. Neurochem. 1993, 61, 2015-2024.
117. Oberley, L.W. Free radicals and diabetes. Free Radic. Biol. Med. 1988, 5, 113-124.
118. Wolff, S.P.; Jiang, Z.Y.; Hunt, J.V. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic. Biol. Med. 1991, 10, 339-352.
119. Baynes, J.W. Role of oxidative stress in development of complications in diabetes. Diabetes 1991, 40, 405-412.
120. Barba, I.; Garcia-Ramirez, M.; Hernandez, C.; Alonso, M.A.; Masmiquel, L.; Garcia-Dorado, D.; Simo, R. Metabolic fingerprints of proliferative diabetic retinopathy: An 1H-NMR-based metabonomic approach using vitreous humor. Invest. Ophthalmol. Vis. Sci. 2010, 51, 4416-4421.
121. Zhang, S.; Zheng, C.; Lanza, I.R.; Nair, K.S.; Raftery, D.; Vitek, O. Interdependence of signal processing and analysis of urine 1H NMR spectra for metabolic profiling. Anal. Chem. 2009, 81, 6080-6088.
122. Klawitter, J.; Haschke, M.; Kahle, C.; Dingmann, C.; Leibfritz, D.; Christians, U. Toxicodynamic effects of ciclosporin are reflected by metabolite profiles in the urine of healthy individuals after a single dose. Br. J. Clin. Pharmacol. 2010, 70, 241-251.
123. Serkova, N.; Fuller, T.F.; Klawitter, J.; Freise, C.E.; Niemann, C.U. H-NMR-based metabolic signatures of mild and severe ischemia/reperfusion injury in rat kidney transplants. Kidney Int. 2005, 67, 1142-1151.
124. Lanz, C.; Patterson, A.D.; Slavik, J.; Krausz, K.W.; Ledermann, M.; Gonzalez, F.J.; Idle, J.R. Radiation metabolomics. 3. Biomarker discovery in the urine of gamma-irradiated rats using a simplified metabolomics protocol of gas chromatography-mass spectrometry combined with random forests machine learning algorithm. Radiat. Res. 2009, 172, 198-212.
125. Chen, C.; Krausz, K.W.; Idle, J.R.; Gonzalez, F.J. Identification of novel toxicity-associated metabolites by metabolomics and mass isotopomer analysis of acetaminophen metabolism in wild-type and Cyp2e1-null mice. J. Biol. Chem. 2008, 283, 4543-4559.
126. Wei, L.; Liao, P.; Wu, H.; Li, X.; Pei, F.; Li, W.; Wu, Y. Toxicological effects of cinnabar in rats by NMR-based metabolic profiling of urine and serum. Toxicol. Appl. Pharmacol. 2008, 227, 417-429.
127. Ohta, T.; Masutomi, N.; Tsutsui, N.; Sakairi, T.; Mitchell, M.; Milburn, M.V.; Ryals, J.A.; Beebe, K.D.; Guo, L. Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male rats. Toxicol. Pathol. 2009, 37, 521-535.
128. Sieber, M.; Wagner, S.; Rached, E.; Amberg, A.; Mally, A.; Dekant, W. Metabonomic study of ochratoxin a toxicity in rats after repeated administration: Phenotypic anchoring enhances the ability for biomarker discovery. Chem. Res. Toxicol. 2009, 22, 1221-1231.
129. Kalhan, S.C.; Guo, L.; Edmison, J.; Dasarathy, S.; McCullough, A.J.; Hanson, R.W.; Milburn, M. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism 2011, 60, 404-413.
130. Viant, M.R.; Hrydziuszko, O.; Silva, M.A.; Perera, M.T.P.R.; Richards, D.A.; Murphy, N.; Mirza, D. Application of metabolomics to investigate the process of human orthotopic liver transplantation: A proof-of-principle study. OMICS: J. Integr. Biol. 2010, 14, 143-150.
131. Moazzami, A.A.; Andersson, R.; Kamal-Eldin, A. Changes in the metabolic profile of rat liver after alpha-tocopherol deficiency as revealed by metabolomics analysis. NMR Biomed. 2011, 24, 499-505.
132. Ellinger-Ziegelbauer, H.; Adler, M.; Amberg, A.; Brandenburg, A.; Callanan, J.J.; Connor, S.; Fountoulakis, M.; Gmuender, H.; Gruhler, A.; Hewitt, P. et al. The enhanced value of combining conventional and ''omics'' analyses in early assessment of drug-induced hepatobiliary injury. Toxicol. Appl. Pharmacol. 2011, 252, 97-111.
133. Niemann, C.U.; Serkova, N.J.; Jackman, M.; Brown, J.L.; Liu, T.; Hirose, R.; Roberts, J.P.; Maher, J.J. Metabolic profiling of livers and blood from obese Zucker rats. J. Hepatol. 2006, 44, 956-962.
134. Soga, T.; Baran, R.; Suematsu, M.; Ueno, Y.; Ikeda, S.; Sakurakawa, T.; Kakazu, Y.; Ishikawa, T.; Robert, M.; Nishioka, T.; Tomita, M. Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. J. Biol. Chem. 2006, 281, 16768-16776.
135. Lindon, J.C.; Keun, H.C.; Ebbels, T.M.; Pearce, J.M.; Holmes, E.; Nicholson, J.K. The Consortium for Metabonomic Toxicology (COMET): Aims, activities and achievements. Pharmacogenomics 2005, 6, 691-699.
136. Gao, P.; Lin, H.L.; Zhang, J. Silent myocardial ischemia is associated with altered plasma phospholipids. J. Clin. Lab. Anal. 2009, 23, 45-50.
137. Tissot van Patot, M.C.; Serkova, N.J.; Haschke, M.; Kominsky, D.J.; Roach, R.C.; Christians, U.; Henthorn, T.K.; Honigman, B. Enhanced leukocyte HIF-1alpha and HIF-1 DNA binding in humans after rapid ascent to 4300 m. Free Radic. Biol. Med. 2009, 46, 1551-1557.
138. Ciborowski, M.; Martin-Ventura, J.L.; Meilhac, O.; Michel, J.B.; Ruperez, F.J.; Tunon, J.; Egido, J.; Barbas, C. Metabolites secreted by human atherothrombotic aneurysms revealed through a metabolomic approach. J. Proteome Res. 2011, 10, 1374-1382.
139. Mayr, M.; Chung, Y.L.; Mayr, U.; Yin, X.K.; Ly, L.; Troy, H.; Fredericks, S.; Hu, Y.H.; Griffiths, J.R.; Xu, Q.B. Proteomic and metabolomic analyses of atherosclerotic vessels from apolipoprotein E-deficient mice reveal alterations in inflammation, oxidative stress, and energy metabolism. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 2135-2142.
140. De Souza, A.I.; Cardin, S.; Wait, R.; Chung, Y.L.; Vijayakumar, M.; Maguy, A.; Camm, A.J.; Nattel, S. Proteomic and metabolomic analysis of atrial profibrillatory remodelling in congestive heart failure. J. Mol. Cell. Cardiol. 2010, 49, 851-863.
141. Xu, Q.B.; Mayr, M.; Siow, R.; Chung, Y.L.; Mayr, U.; Griffiths, J.R. Proteomic and metabolomic analysis of vascular smooth muscle cells - Role of PKC delta. Circ. Res. 2004, 94, E87-E96.
142. Cascante, M.; Benito, A.; Zanuy, M.; Vizan, P.; Marin, S.; de Atauri, P. Metabolic network adaptations in cancer as targets for novel therapies. Biochem. Soc. Trans. 2010, 38, 1302-1306.
143. Britz-McKibbin, P.; Lee, R. Metabolomic studies of radiation-induced apoptosis of human leukocytes by capillary electrophoresis-mass spectrometry and flow cytometry: Adaptive cellular responses to ionizing radiation. Electrophoresis 2010, 31, 2328-2337.
144. Pacak, K. Phaeochromocytoma: A catecholamine and oxidative stress disorder. Endocr. Regul. 2011, 45, 65-90.
145. Bahn, S.; Holmes, E.; Tsang, T.M.; Huang, J.T.J.; Leweke, F.M.; Koethe, D.; Gerth, C.W.; Nolden, B.M.; Gross, S.; Schreiber, D.; Nicholson, J.K. Metabolic profiling of CSF: Evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med. 2006, 3, 1420-1428.
146. Kaddurah-Daouk, R.; McEvoy, J.; Baillie, R.A.; Lee, D.; Yao, J.K.; Doraiswamy, P.M.; Krishnan, K.R.R. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol. Psychiat. 2007, 12, 934-945.
147. Johansen, K.K.; Wang, L.; Aasly, J.O.; White, L.R.; Matson, W.R.; Henchcliffe, C.; Beal, M.F.; Bogdanov, M. Metabolomic profiling in LRRK2-related Parkinson's disease. PLoS one 2009, 4, 1-9.
148. Zhang, S.; Nagana Gowda, G.A.; Asiago, V.; Shanaiah, N.; Barbas, C.; Raftery, D. Correlative and quantitative 1H NMR-based metabolomics reveals specific metabolic pathway disturbances in diabetic rats. Anal. Biochem. 2008, 383, 76-84.
149. Portilla, D.; Schnackenberg, L.; Beger, R.D. Metabolomics as an extension of proteomic analysis: Study of acute kidney injury. Semin. Nephrol. 2007, 27, 609-620.
150. Andreadou, I.; Papaefthimiou, M.; Zira, A.; Constantinou, M.; Sigala, F.; Skaltsounis, A.L.; Tsantili-Kakoulidou, A.; Iliodromitis, E.K.; Kremastinos, D.T.; Mikros, E. Metabonomic identification of novel biomarkers in doxorubicin cardiotoxicity and protective effect of the natural antioxidant oleuropein. NMR Biomed. 2009, 22, 585-592.